Get the Stockscreener App
9.28
1.98%
0.18
After Hours:
9.29
0.010
+0.11%
Gh Research Plc stock is traded at $9.28, with a volume of 58,124.
It is up +1.98% in the last 24 hours and up +21.31% over the past month.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.
See More
Previous Close:
$9.10
Open:
$9.16
24h Volume:
58,124
Relative Volume:
1.02
Market Cap:
$459.93M
Revenue:
-
Net Income/Loss:
$-32.32M
P/E Ratio:
-13.51
EPS:
-0.687
Net Cash Flow:
$-36.14M
1W Performance:
-15.25%
1M Performance:
+21.31%
6M Performance:
-32.26%
1Y Performance:
+38.51%
1-Day Range:
$8.67
$9.40
1-Week Range:
$8.66
$11.07
52-Week Range:
$5.05
$14.99
Gh Research Plc Stock (GHRS) Company Profile
Compare GHRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GHRS
Gh Research Plc
|
9.28 | 459.93M | 0 | -32.32M | -36.14M | -0.687 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Gh Research Plc Stock (GHRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-16-22 | Initiated | H.C. Wainwright | Buy |
| Jun-16-22 | Initiated | ROTH Capital | Buy |
Gh Research Plc Stock (GHRS) Latest News
GH Research (NASDAQ:GHRS) Trading Down 0.8%Here's What Happened - MarketBeat
GH Research (NASDAQ:GHRS) Stock Price Up 1.4%Here's Why - MarketBeat
GH Research’s (GHRS) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
(GHRS) Technical Data - Stock Traders Daily
HC Wainwright Reduces Earnings Estimates for GH Research - Defense World
GH Research (NASDAQ:GHRS) Shares Down 5.1%What's Next? - MarketBeat
Brokers Offer Predictions for GH Research FY2024 Earnings - MarketBeat
Does GH Research (GHRS) Have the Potential to Rally 225.18% as Wall Street Analysts Expect? - MSN
GH Research (NASDAQ:GHRS) Trading Down 1.7%Here's What Happened - MarketBeat
H.C. Wainwright maintains buy rating on GHRS shares, cites Q3 report By Investing.com - Investing.com South Africa
H.C. Wainwright maintains buy rating on GHRS shares, cites Q3 report - Investing.com Canada
3 Fast-Growing Stocks Analysts See Doubling in Price - MSN
GH Research (NASDAQ:GHRS) Trading Up 2%Time to Buy? - MarketBeat
HC Wainwright Reiterates "Buy" Rating for GH Research (NASDAQ:GHRS) - MarketBeat
Canaccord Genuity Group Issues Pessimistic Forecast for GH Research (NASDAQ:GHRS) Stock Price - Defense World
GH Research Q3 2024 Results and Clinical Updates - TipRanks
GH Research (NASDAQ:GHRS) Trading 1.2% HigherTime to Buy? - MarketBeat
Short Interest in GH Research PLC (NASDAQ:GHRS) Increases By 7.3% - MarketBeat
GH Research (NASDAQ:GHRS) Stock Price Up 3.3%Here's Why - MarketBeat
GH Research shares hold Buy rating as Canaccord anticipates pivotal durability data in 2025 - Investing.com
GH Research (NASDAQ:GHRS) Stock Price Up 0.1%Time to Buy? - MarketBeat
RA Capital Management, L.P. Increases Stake in GH Research PLC - GuruFocus.com
Health Stocks Slide as Trump Picks Industry Skeptic Kennedy - BNN Bloomberg
GH Research reports deeper losses as DMT clinical trial costs mount - Green Market Report
GH Research (NASDAQ:GHRS) Shares Up 0.2%Here's What Happened - MarketBeat
Lynx1 Capital Management LP's Strategic Acquisition in GH Resear - GuruFocus.com
GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewswire
GH Research Completes Phase 2b Depression Trial Enrollment, Reports $12.1M Q3 Loss | GHRS Stock News - StockTitan
GH Research (NASDAQ:GHRS) Stock Price Up 3.8%Here's Why - MarketBeat
GH Research (NASDAQ:GHRS) Stock Price Up 4.1%Still a Buy? - MarketBeat
(GHRS) Pivots Trading Plans and Risk Controls - Stock Traders Daily
GH Research (NASDAQ:GHRS) Trading 3.1% HigherHere's What Happened - MarketBeat
Intellia Thera CS (NTLA-Q) QuotePress Release - The Globe and Mail
Guardant Health, Inc. (NASDAQ:GH) Shares Acquired by US Bancorp DE - Defense World
We Think GH Research (NASDAQ:GHRS) Can Afford To Drive Business Growth - Yahoo Finance
GH Research (NASDAQ:GHRS) Trading Up 0.6%What's Next? - MarketBeat
Major Depressive Disorder Clinical Trials 2024: FDA Approvals, - openPR
GH Research (NASDAQ:GHRS) Trading Down 0.9%Should You Sell? - MarketBeat
GH Research (NASDAQ:GHRS) Trading Up 2.1%What's Next? - MarketBeat
GH Research (NASDAQ:GHRS) Stock Price Up 0.6%Here's Why - MarketBeat
GH Research (NASDAQ:GHRS) Trading Up 0.7%Here's What Happened - MarketBeat
abrdn plc Raises Stock Holdings in Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
(GHRS) On The My Stocks Page - Stock Traders Daily
GH Research (NASDAQ:GHRS) Shares Up 2.2%Time to Buy? - MarketBeat
Standard Chartered Bank Ghana PLC (SCB.gh) Q32024 Interim Report - AfricanFinancials
Gh Research Plc Stock (GHRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):